It should be noted that patients not included in the follow up analysis had a higher prevalence of hypogonadism and higher IL-6 levels, compared to patients who were analyzed at follow up, and thus the incidence of metabolic syndrome among young cancer survivors might be underestimated in this study. The gene discussed is IL6; the disease is metabolic syndrome.